Results for the substance zilucoplan

Zilucoplan is an investigational drug used in the treatment of rare autoimmune diseases, such as generalized myasthenia gravis (MG). It is a complement C5 inhibitor, a protein involved in the activation of the complement system, which plays a key role in the immune response. By blocking the activity of complement C5, zilucoplan reduces inflammation and tissue damage caused by autoantibodies.

The mechanism of action of zilucoplan involves specifically binding to the C5 protein, thereby preventing its cleavage into C5a and C5b fragments. This process inhibits the formation of the membrane attack complex (MAC), which is responsible for the destruction of healthy cells in autoimmune diseases. Through this mechanism, zilucoplan helps reduce symptoms and improve the quality of life for patients with myasthenia gravis.

Zilucoplan is administered as a subcutaneous injection, typically once daily, as directed by a physician. It is primarily used in clinical trials and is intended for patients who do not respond adequately to other therapies or who require additional treatment options.

While promising, zilucoplan may cause side effects. The most common include injection site reactions, headache, fatigue, and upper respiratory tract infections. In rare cases, more serious reactions such as severe infections caused by encapsulated bacteria (e.g., meningococcus) may occur. Close monitoring of patients during treatment is essential, and appropriate vaccinations should be administered to reduce the risk of infections.